Group 1 - The core issue involves the investigation of Jiang Wei, a major shareholder and actual controller of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading [1] - The investigation pertains solely to Jiang Wei as an individual and does not involve the company's stock or daily operations, indicating no significant impact on the company's regular business activities [2] Group 2 - On May 7, Haohai Biological Technology's stock closed at 53.17 yuan per share, down 0.21%, with a market capitalization of 12.4 billion yuan [3] - The company recently announced a stock buyback, having repurchased approximately 1.49 million A-shares, accounting for 0.64% of the total share capital, with a total transaction amount of about 85.94 million yuan [3] - For the fiscal year 2024, Haohai Biological Technology reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, a year-on-year increase of 1.04%, indicating stagnation in growth [3] - The overall gross margin decreased from 70.46% to 69.89%, despite the increasing revenue share from high-margin hyaluronic acid products, due to significant price declines in other products [3] Group 3 - In Q1 2025, Haohai Biological Technology reported total revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit attributable to shareholders of 90.31 million yuan, down 7.41% [4] - The decline in performance reflects intense competition in the hyaluronic acid and medical aesthetics market, with emerging alternative materials reshaping the landscape [4] - Research indicates that recombinant collagen may replicate the success of hyaluronic acid, supported by continuous improvements in supply chain policies and technological breakthroughs [4]

Summary of the Conference Call Records Industry Overview - The beauty and personal care industry is experiencing an increase in penetration rates and rising prices, showing stronger growth compared to traditional food and beverage sectors, leading new consumption trends [1][7] - Domestic brands are rapidly rising in the beauty and personal care market, replacing foreign brands, particularly Japanese and Korean brands, which are showing significant declines [1][3] Key Financial Performance - **Personal Care Segment**: - 2024 revenue growth of 19% and net profit growth of 25% - Q1 2025 revenue growth of 29% and profit growth of 13%, driven by product innovation and Douyin channel [1][6] - **Medical Aesthetics Segment**: - 2024 revenue growth of 16% and net profit growth of 22% - Q1 2025 revenue and profit remained flat, with significant internal differentiation [1][9] - **Cosmetics Industry**: - 2024 revenue growth of 11% and net profit decline of 9% (11% growth after excluding anomalies) - Some companies like Juzhi Biotechnology and Mao Ge Ping performed exceptionally well [1][10] Channel Performance - Douyin channel is noted for its dual role in marketing and sales, with high initial costs but potential for improved profitability as brand influence expands to other channels [4][8] - In April 2025, beauty brands on Douyin showed strong performance, with several brands achieving over 100% growth [11] Company-Specific Insights - **Ruo Yuchen**: - Q1 2025 revenue and profit growth exceeded 200% for its free brand and over 150% for its household cleaning brand [12] - **Deng Kang Oral Care**: - Q1 2025 revenue and profit growth of 15%-20%, with online channels showing over 200% growth [14] - **Polaire**: - Q1 2025 saw unexpected profit growth due to improved gross margins and optimized sales expenses [16] - **Mao Ge Ping**: - April 2025 Douyin channel growth of over 30% [17] - **Perfect Bio**: - Q1 2025 revenue growth of 28% and net profit close to 30% [18] - **Runben**: - Q1 2025 revenue growth of 44%, with a focus on new product launches [19] Market Trends and Investment Recommendations - The beauty and personal care sector is expected to continue leading new consumption trends, with investment strategies focusing on companies with strong innovation capabilities and those showing positive changes [1][7][26] - Recommended stocks include Ruo Yuchen, Deng Kang Oral Care, and Runben in the personal care segment, and high-end domestic brands like Mao Ge Ping and companies in the collagen segment like Juzhi Biotechnology [26] Additional Insights - The beauty and personal care sector is more sensitive to product demand, innovation, and channel changes compared to other consumer goods, providing a natural premium and innovation potential [24] - The overall market for personal care, beauty, and medical aesthetics is expected to show strong growth, driven by product innovation and structural opportunities [25]

Investment Rating - The investment rating for Marubi Biotechnology (丸美生物) is not explicitly stated in the provided documents, but the overall sentiment appears positive based on the performance metrics and growth projections. Core Insights - Marubi Biotechnology reported a revenue of 2.97 billion yuan in 2024, representing a year-over-year increase of 33.4%, with a net profit attributable to shareholders of 342 million yuan, up 31.7% year-over-year [1] - The company is experiencing continuous growth driven by both product innovation and technological advancements, positioning itself as a leader in the collagen industry [5] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 2.97 billion yuan and a net profit of 342 million yuan, with a significant increase in net profit margin [1] - For Q1 2025, revenue reached 847 million yuan, reflecting a year-over-year growth of 28% [1] - The gross profit margin improved to 74.6% in 2024, with a further increase to 76% in Q1 2025 [4] Product and Brand Development - The product structure is continuously optimized, with skincare, eye care, cleansing, and beauty products generating revenues of 1.125 billion, 689 million, 241 million, and 913 million yuan respectively in 2024 [2] - The eye care segment saw significant growth, particularly with the "胜肽小红笔眼霜" product, which achieved an online GMV of 533 million yuan, up 146% year-over-year [2] Sales Channels - Online sales accounted for 25.41 billion yuan in 2024, growing by 35.8% year-over-year, while offline sales reached 4.27 billion yuan, up 20.8% [3] - The online sales proportion increased to 86%, indicating a strong digital presence and effective multi-platform strategies [3] Cost Management and Efficiency - The company maintained stable expense ratios across sales, management, and R&D, with a sales expense ratio of 55% in 2024 [4] - Inventory turnover days improved to approximately 90.2 days in 2024, indicating enhanced operational efficiency [4] Future Projections - The forecast for net profit attributable to shareholders is projected to be 450 million yuan in 2025, 582 million yuan in 2026, and 692 million yuan in 2027, reflecting a consistent growth trajectory [8] - The expected P/E ratios for 2025, 2026, and 2027 are 38.9X, 30.1X, and 25.3X respectively, suggesting a favorable valuation outlook [6]

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [6][8]. Core Insights - The company achieved a revenue of 1.443 billion yuan in 2024, representing a year-on-year increase of 84.92%, with a net profit attributable to shareholders of 732 million yuan, up 144.27% year-on-year [3]. - The first quarter of 2025 saw a revenue of 367 million yuan, a year-on-year growth of 62.51%, and a net profit of 169 million yuan, reflecting a 66.25% increase year-on-year [3]. - The company is a leader in the collagen protein market, with projected net profits of 1.105 billion yuan, 1.598 billion yuan, and 2.145 billion yuan for 2025, 2026, and 2027 respectively, showing growth rates of 50.9%, 44.6%, and 34.2% [6]. Revenue Breakdown - Medical device sales drove overall revenue growth, with medical devices generating 1.254 billion yuan in 2024, a year-on-year increase of 84.37% [4]. - Functional skincare products contributed 142 million yuan in revenue, up 86.83% year-on-year, with significant growth from the "重源®" and "ProtYouth®" brands [4]. - Revenue from raw materials and other segments reached 46 million yuan, reflecting an 89.07% increase year-on-year, attributed to stable procurement from brand clients and increased product recognition [4]. Profitability Metrics - The company's net profit margin for 2024 was 50.75%, an increase of 12.33 percentage points year-on-year, while the non-GAAP net profit margin was 49.36%, up 12.73 percentage points [5]. - Gross margin for 2024 was reported at 92.02%, with a slight decrease in the first quarter of 2025 to 90.11% [5]. - The company plans to implement an equity incentive plan, reflecting confidence in long-term growth, with performance targets set for net profits over the next three years [6]. Financial Forecasts - Projected revenues for 2025, 2026, and 2027 are 2.154 billion yuan, 3.076 billion yuan, and 4.198 billion yuan respectively, with growth rates of 49.3%, 42.8%, and 36.5% [7][10]. - The forecasted net profit for 2025 is 1.105 billion yuan, with a growth rate of 50.9% [7][10]. - The price-to-earnings (PE) ratios for 2025, 2026, and 2027 are estimated at 30x, 21x, and 16x respectively, indicating a favorable valuation trend [6][10].

Core Viewpoint - The performance of beauty companies listed in 2024 reflects a challenging environment, with many traditional giants facing significant losses while some emerging brands show strong growth [1][2]. Industry Overview - In 2024, China's total retail sales of consumer goods grew by 3.5%, but the retail sales of cosmetics declined by 1.1%, amounting to 435.65 billion yuan [2]. - The overall industry is experiencing a downturn, leading to price cuts and store closures by several foreign brands [2]. - Major companies like Shanghai Jahwa reported a loss of 833 million yuan, highlighting the struggles of established players [2][4]. Company Performance - As of April 27, 2024, 15 A-share cosmetic companies reported a total revenue of 50.081 billion yuan, a year-on-year increase of 3.59%, but net profit fell to 3.765 billion yuan, down from 5.127 billion yuan [4]. - Notable performances include: - Proya achieved revenue of 10.778 billion yuan, becoming the first domestic beauty brand to surpass 10 billion yuan [2][11]. - Shanghai Jahwa's revenue decreased by 13.93% to 5.679 billion yuan, with a net profit loss of 833 million yuan [6]. - Betaini reported revenue of 5.736 billion yuan, up 3.87%, but net profit fell by 33.53% to 503 million yuan [8]. - Huaxi Biological's revenue dropped by 11.61% to 5.371 billion yuan, with net profit down 70.59% to 174 million yuan [8]. Emerging Brands - New entrants like Gu Yu Biotechnology are preparing to enter the capital market, showcasing strong growth with a revenue of 4 billion yuan and GMV exceeding 5 billion yuan [14][15]. - Gu Yu's success is attributed to its focus on a unique ingredient and effective online marketing strategies, although its reliance on a single product category may pose future challenges [15]. Market Trends - The market is witnessing a shift where traditional giants are retracting while new players are emerging, indicating a potential reshaping of the industry landscape [10][14]. - The global beauty market is expected to see a coexistence of domestic brands leading in niche segments while foreign brands focus on high-end markets [16].

Summary of the Conference Call for Perfect Diary (完美生物技术股份有限公司) Company Overview - The conference call discusses the financial performance and strategic initiatives of Perfect Diary, a leading player in the beauty and skincare industry, particularly focusing on its transformation and growth in the market. Key Financial Performance - **Q1 2025 Revenue**: 847 million yuan, a year-on-year increase of 28%, marking nine consecutive quarters of revenue and profit growth [2][4] - **2024 Revenue**: 2.97 billion yuan, a year-on-year increase of 33.44%, with main business revenue accounting for 99.94% [4] - **Gross Margin**: 2024 gross margin at 73.7%, up 3.01 percentage points year-on-year; Q1 2025 gross margin at 76.05%, up 1.45 percentage points year-on-year [2][5] - **Net Profit**: 2024 net profit attributable to shareholders at 342 million yuan, up 31.69% year-on-year; Q1 2025 net profit at 135 million yuan, up 22.07% year-on-year [2][5] Brand Performance - **Perfect Brand Revenue**: 2 billion yuan in 2024, accounting for 69% of total revenue, with eye products contributing 33% [6] - **PL Brand Revenue**: 900 million yuan in 2024, accounting for 30% of total revenue, with foundation products achieving over 100 million yuan in GMV [6] - **Online vs. Offline Growth**: Online channel revenue grew by 36% while offline grew by 21%, indicating a stronger performance in online sales [6] Research and Development - **R&D Investment**: 73.5 million yuan in 2024, an 18% increase year-on-year; a total of 596 patents applied, with 319 granted [8] - **Industry Leadership**: The company leads in R&D and patent reserves, having published 53 papers and participated in 82 standard-setting initiatives [8] Marketing and Brand Strategy - **Marketing Shift**: Transitioned from "eye care expert" to "focusing on reducing fine lines," emphasizing user connection and brand value [4][11] - **Product Strategy**: Focus on big product strategies, with significant upgrades to key products like the small red pen eye cream [12][16] - **Social Media Marketing**: Achieved significant engagement through short videos, with 1.2 billion views and high new customer conversion rates [19][25] Sustainability and Corporate Governance - **Sustainability Initiatives**: Selected as a green factory in Guangdong, with multiple products achieving carbon neutrality certifications [10] - **Dividend Policy**: Consistent dividends since 2019, totaling 900 million yuan, reflecting a commitment to shareholder returns [9] Future Outlook - **Growth Strategy**: Plans to enhance technology innovation and operational efficiency, aiming to solidify its position as a leading company in the industry [14][51] - **Product Expansion**: Introduction of new products like the collagen small gold needle and the whitening essence, with sales targets set for significant growth [52] Challenges and Responses - **Market Competition**: Acknowledgment of fierce competition in the sunscreen market, with a focus on anti-aging products [55] - **Channel Strategy**: Addressing challenges in offline sales by enhancing customer experience and maintaining a robust online presence [27][46] Conclusion - Perfect Diary demonstrates strong financial performance, innovative marketing strategies, and a commitment to sustainability, positioning itself for continued growth in the competitive beauty industry. The company is focused on leveraging technology and enhancing customer engagement to drive future success.

以下文章来源于财经天下WEEKLY ，作者财经天下 财经天下WEEKLY . 《财经天下》周刊官方账号，提供有品质的深度报道，讲述中国企业在时代浪潮中的精彩故事。 来源丨财经天下WEEKLY（ID：cjtxweekly） 作者丨林木 编辑丨吴跃 图源丨Midjourney 因为陷入"EGF（表皮生长因子）罗生门"，可复美近期被推上风口浪尖。 不久前，有消费者反映可复美产品"违规添加EGF"。随后可复美母公司巨子生物予以否认，称"旗下所有 产品均未添加"。伴随着舆论发酵，社媒平台上，看客们吵得沸沸扬扬，力挺声、质疑声四起，也让"可 复美"这个名字被更多人知晓。 做过医美或者皮肤敏感的消费者，大多对"可复美"三个字不陌生。这个主打皮肤修复的品牌，早年间主 要深耕院线渠道，之后乘上直播电商风口，进入更多人视野，撬开更多钱包。过去6年，其母公司巨子生 物营收从9.57亿元涨至55.39亿元，翻了5倍多。 2024年，巨子生物一举超越珀莱雅，成为市值最高的国货美妆公司，此后一直保持至今。公司创始人， 现年59岁的陕西人范代娣，也因此登顶国货美妆首富。 95后女生冯琳第一次知道"可复美"，是被皮肤敏感的姐姐种草的。202 ...

4月22日丸美生物董事会主席兼CEO孙怀庆在第五届重组胶原蛋白科学论坛上提到，随着丸美生物主导 制定的《国家重组胶原蛋白行业标准》进入最后评审阶段，公司已经从最初的"吹哨人"，变成了现在的 标准制定者和行业引领者。 弗若斯特沙利文数据显示，中国重组胶原蛋白产品市场规模预计将从2022年的185亿元增长至2027年的 1083亿元，年复合增长率为42.4%，重组胶原蛋白产品的市场渗透率也将大幅提升，到2027年将提高至 62.3%。 本报讯 （记者王镜茹） 4月26日广东丸美生物（603983）技术股份有限公司（以下简称"丸美生物"）发布一季度业绩。一季度 公司实现总营业收入8.47亿元，同比增长28.01%；归母净利润1.35亿元，同比增长22.07%。 同日，丸美生物发布2024年年报。2024年公司营业收入29.70亿元，同比增长33.44%；归母净利润3.42 亿元，同比增长31.69%。其中，主品牌丸美实现营业收入20.55亿元，主营收入占比69.24%；PL恋火品 牌实现营业收入9.05亿元，主营收入占比30.51%；毛利率73.7%，同比上升3.01个百分点，主要系产品 结构及成本控制不断优化所致 ...

重组胶原蛋白行业在技术、工艺上持续进步，继I型、III型后在XVII型、IV型以及多型别组合方面再现突破；各龙头公司在结构解析、发酵制 备、产品化、商业化方面的闭环能力更为成熟。格局方面，各公司均综合布局"妆&二类械&消费/严肃医疗三类械"，同时又在各自擅长的品类深 耕，差异化竞争。最后，中国重组胶原蛋白全球化提速，"原料、妆、械"全面出海。 ▍ 皮肤具备多种生理功能，胶原蛋白分布广且功效多样。 皮肤呈现层叠结构，由表皮、真皮、皮下组织构成。皮肤具有屏障、吸收、分泌和排泄、感觉、体温调节、物质代谢、免疫等多种功能，直接 参与全身的各种功能活动并维持内环境的稳定。人体内2 9种型别胶原蛋白，各型别功能和分布有所区别。目前人类研究发现的胶原蛋白共2 9 种，当前市场上开发和商业化较多的为I型和III型胶原蛋白。双光子显微成像等技术能够有效检验重组胶原蛋白透皮吸收情况。 文 ｜ 徐晓芳 杜一帆 张琳 宋硕 徐嘉琪 皮肤生理功能梳理 | 序号 功能 | | 功能解析 | | --- | --- | --- | | 1 | 屏障功能 | 一方面,保护机体内各种器官组织免受外界环境中机械的、物理的、化学的和生物 | | ...

Core Insights - The medical aesthetics industry is experiencing significant revenue declines among major players, indicating a painful transformation phase for traditional companies [1][2][5] - Huaxi Biological, Aimeike, and Haohai Biological show varying degrees of revenue decline, highlighting differences in business structure and strategic deployment [1][2] - The industry is facing fundamental changes, raising concerns about which companies may fall behind in this transformation [1][8] Company Performance - Huaxi Biological reported a 20.77% year-on-year revenue decline in Q1 2025, with revenue shrinking to 1.078 billion yuan [1] - Aimeike's revenue decreased by 17.90% to 663 million yuan, while Haohai Biological's revenue fell by 4.25% to 619 million yuan [1] - Huaxi Biological's net profit plummeted from 961 million yuan in 2022 to 174 million yuan in 2024, with a further 58.13% decline in Q1 2025 [2][4] Strategic Adjustments - Huaxi Biological is undergoing a significant management overhaul, with leadership changes aimed at addressing operational challenges and improving performance [3][4] - The company is focusing on new fields such as glycoscience and cell biology, which has led to increased management costs [2][3] - Aimeike is shifting its strategy to accelerate product updates and pursue acquisitions in new areas like botulinum toxin and semaglutide [5][6] Market Dynamics - The medical aesthetics market is witnessing intense competition, particularly in the hyaluronic acid segment, raising concerns about whether the market has peaked [8][9] - New materials like hydroxyapatite and recombinant collagen are emerging as potential competitors to hyaluronic acid, indicating a shift in market dynamics [8][9] - Regulatory challenges and lengthy approval processes for medical products are significant barriers to industry growth, impacting companies' ability to innovate [9][10] Future Outlook - Huaxi Biological's turnaround efforts may take time to yield results, especially given its high marketing expenditures [10] - Aimeike's success will depend on the speed of product approvals and market acceptance of its diversified product strategy [6][10] - Haohai Biological is exploring new materials to drive growth, but its performance is still affected by pricing pressures from centralized procurement policies [7][10]